FDA Returns Disappointing News for ALS Stem Cell Therapy
PLOS: DNA Science
OCTOBER 19, 2023
.” The ALS Association had previously stated “Our Position on NurOwn”: “After BrainStorm shared that its Phase 3 trial of NurOwn did not meet its primary or secondary endpoints, we have consistently requested access to the full data package so we could try to better understand its effect on people living with ALS.
Let's personalize your content